Concomitant Guillain-Barre syndrome with COVID-19: a case report.
COVID-19
Case report
Guillain-Barre syndrome
SARS-CoV-2
Journal
BMC neurology
ISSN: 1471-2377
Titre abrégé: BMC Neurol
Pays: England
ID NLM: 100968555
Informations de publication
Date de publication:
23 Mar 2021
23 Mar 2021
Historique:
received:
24
07
2020
accepted:
18
03
2021
entrez:
24
3
2021
pubmed:
25
3
2021
medline:
7
4
2021
Statut:
epublish
Résumé
During the Coronavirus disease 2019 (COVID-19) pandemic, different neurological manifestations have been observed. However, only a few cases of Guillain-Barre syndrome (GBS) and COVID-19 have been reported. Therefore, the aim of this study is to investigate a case of concomitant GBS with COVID-19 in Colombia. A 39-year-old woman was admitted to a teaching hospital in Barranquilla, Colombia with a history of progressive general weakness with lower limb dominance. Previous symptoms such as ageusia, anosmia and intense headache were reported. Upon admission, facial diplegia, quadriparesis with lower extremity predominance and Medical Research Council muscular strength of 2/5 in the lower limbs and 4/5 in the upper limbs were reported. During clinical evolution, due to general areflexia, hypertensive emergency and progressive diaphragmatic weakness, the patient was admitted to an intensive care unit. The cerebrospinal fluid analysis showed protein-cytological dissociation and the GBS diagnosis was confirmed via a nerve conduction and electromyography test. With regard to the symptoms before hospitalisation, SARS-CoV-2 diagnostic testing was performed with positive results in the second test. The patient was managed with supportive care and was discharged after 20 days of hospitalization with clinical improvement. Only a few cases of COVID-19 with GBS have been reported. Different subtypes have been previously identified, such as Miller-Fisher syndrome and dysautonomic GBS with SARS-CoV-2 infection. This study investigated the first confirmed case of COVID-19 with concomitant GBS in Colombia. In patients with GBS, several viral and bacterial pathogens have been found in case-control studies but the factors that induce the immune-mediated destruction of the nerve tissues have not been determined. Further studies are needed to determine the possible association between COVID-19 exposure and GBS.
Sections du résumé
BACKGROUND
BACKGROUND
During the Coronavirus disease 2019 (COVID-19) pandemic, different neurological manifestations have been observed. However, only a few cases of Guillain-Barre syndrome (GBS) and COVID-19 have been reported. Therefore, the aim of this study is to investigate a case of concomitant GBS with COVID-19 in Colombia.
CASE PRESENTATION
METHODS
A 39-year-old woman was admitted to a teaching hospital in Barranquilla, Colombia with a history of progressive general weakness with lower limb dominance. Previous symptoms such as ageusia, anosmia and intense headache were reported. Upon admission, facial diplegia, quadriparesis with lower extremity predominance and Medical Research Council muscular strength of 2/5 in the lower limbs and 4/5 in the upper limbs were reported. During clinical evolution, due to general areflexia, hypertensive emergency and progressive diaphragmatic weakness, the patient was admitted to an intensive care unit. The cerebrospinal fluid analysis showed protein-cytological dissociation and the GBS diagnosis was confirmed via a nerve conduction and electromyography test. With regard to the symptoms before hospitalisation, SARS-CoV-2 diagnostic testing was performed with positive results in the second test. The patient was managed with supportive care and was discharged after 20 days of hospitalization with clinical improvement.
CONCLUSIONS
CONCLUSIONS
Only a few cases of COVID-19 with GBS have been reported. Different subtypes have been previously identified, such as Miller-Fisher syndrome and dysautonomic GBS with SARS-CoV-2 infection. This study investigated the first confirmed case of COVID-19 with concomitant GBS in Colombia. In patients with GBS, several viral and bacterial pathogens have been found in case-control studies but the factors that induce the immune-mediated destruction of the nerve tissues have not been determined. Further studies are needed to determine the possible association between COVID-19 exposure and GBS.
Identifiants
pubmed: 33757457
doi: 10.1186/s12883-021-02162-3
pii: 10.1186/s12883-021-02162-3
pmc: PMC7985584
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
135Références
Lancet Infect Dis. 2020 May;20(5):547-548
pubmed: 32311323
N Engl J Med. 2016 Oct 20;375(16):1513-1523
pubmed: 27705091
Neurology. 2020 Aug 4;95(5):e601-e605
pubmed: 32303650
J Neurovirol. 2020 Dec;26(6):964-966
pubmed: 32918164
Lancet Neurol. 2020 May;19(5):383-384
pubmed: 32246917
Intern Med. 2008;47(17):1539-42
pubmed: 18758131
Clin Infect Dis. 2011 Apr 1;52(7):837-44
pubmed: 21427390
Can J Neurol Sci. 2021 Jan;48(1):9-24
pubmed: 32753076
Lancet Microbe. 2020 Aug;1(4):e149
pubmed: 32835345
Neurology. 2020 Aug 25;95(8):e1060-e1070
pubmed: 32482845
Neuroepidemiology. 2011;36(2):123-33
pubmed: 21422765
J Med Virol. 2021 Jan;93(1):66-68
pubmed: 32497288
Lancet Infect Dis. 2020 May;20(5):533-534
pubmed: 32087114
Curr Allergy Asthma Rep. 2011 Jun;11(3):197-204
pubmed: 21451970
J Peripher Nerv Syst. 2015 Jun;20(2):72-8
pubmed: 26115201
N Engl J Med. 2020 Jun 25;382(26):2574-2576
pubmed: 32302082
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Lancet Neurol. 2020 Sep;19(9):767-783
pubmed: 32622375
J Clin Neurosci. 2020 Jun;76:233-235
pubmed: 32312628